Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRST study of dostarlimab + niraparib with platinum-based chemotherapy versus standard of care in first-line advanced ovarian cancer
NL-OMON54558Phase 3Recruiting
- Sponsor
- TESARO, Inc.
- Start
- Jan 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dostarlimab, niraparib, paclitaxel and carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by TESARO, Inc. Primary endpoints: Progression-free survival in PD-L1 positive patients and Progression-free survival in all patients. Started Jan 2020; status: recruiting.
02
Drugs
dostarlimabniraparibpaclitaxelcarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON54558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54558.